Un nuevo caso de NEM 2B | Endocrinología y Nutrición

Información del artículo

La neoplasia endocrina múltiple es un síndrome de herencia autosómica dominante caracterizado por el desarrollo de tumores endocrinos, cuyo componente más común es el carcinoma medular de tiroides (CMT). Este síndrome se asocia a mutaciones en el protooncogén RET (cromosoma 10). El cribado genético de familiares de enfermos con esta entidad es clave, ya que se trata de una entidad potencialmente mortal. Presentamos un caso de neoplasia endocrina múltiple 2B que acudió a consulta por una tumoración tiroidea y anomalías morfológicas en los labios. Destacamos la importancia de la sospecha clínica de esta enfermedad para un diagnóstico y un tratamiento adecuados.

Palabras clave:

Neoplasia endocrina múltiple 2

Carcinoma medular de tiroides

Multiple endocrine neoplasia (MEN) syndrome is an autosomal dominantly inherited disease characterized by the development of endocrine tumors. The most common component of MEN 2 is medullary thyroid carcinoma. This syndrome is associated with protooncogene RET (chromosome 10) mutation. Genetic screening of members of patients’ families is cruzial due to its potential severity. We describe a patient with NEM 2B syndrome who presented with a thyroid tumor and morphological changes in his lips. We highlight the importance of clinical suspicion for correct diagnosis and appropriate treatment.

Key words:

Multiple endocrine neoplasia

Medullary thyroid cancer

El Texto completo está disponible en PDF

Bibliografía

[1.]

R.A. De Lellis.

Biology of disease, multiple endocrine neoplasia syndromes revisted. Clinical, morfologic and molecular features.

Lab Invest, 72 (1995), pp. 494-505

Medline

[2.]

J.A. Carney.

Familial multiple endocrine neoplasia syndromes: components, clasification and nomenclature.

J Intern Med, 243 (1998), pp. 425-432

Medline

[3.]

Z. Baloch, P. Carayon, B. Conte-Devolx, L.M. Demers, U. Feldt- Rasmussen, J.F. Henry, et al.

Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.

Thyroid, 13 (2003), pp. 3-126

http://dx.doi.org/10.1089/105072503321086962 | Medline

[4.]

L.M. Mulligan, J.B.J. Kwok, C.S. Healy, M.J. Elsdon, C. Eng, E. Gardner, et al.

Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Nature, 363 (1993), pp. 458-460

http://dx.doi.org/10.1038/363458a0 | Medline

[5.]

A. Ullrich, J. Schlessinger.

Signal transduction by receptors with tyrosine kinase activity.

Cell, 61 (1990), pp. 203-212

Medline

[6.]

C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R.F. Gagel, et al.

The relationship between specific RET proto-oncogene mutation and disease phenotype in multiple endocrine neoplasia type 2: international RET Mutation Consortium Analysis.

JAMA, 276 (1996), pp. 1575-1579

Medline

[7.]

H.F. Vasen, M. Van der Feltz, F. Raue, A.N. Kruseman, H.P.F. Koppeschar, G. Pieters, et al.

The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases.

Arch Intern Med, 152 (1992), pp. 1250-1252

Medline

[8.]

H. Tsao.

Update on familial cancer syndromes and the skin.

J Am Acad Dermatol, 42 (2000), pp. 939-969

Medline

[9.]

M. Schlumberger, F. Pacini.

Medullary thyroid carcinoma.

Thyroid tumors,

[10.]

M. Torre, G. Martucciello, I. Ceccherini, M. Lerone, M. Aicardi, C. Gambini, et al.

Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B in pediatric patients.

Pediatr Surg Int, 18 (2002), pp. 378-383

http://dx.doi.org/10.1007/s00383-002-0824-1 | Medline

[11.]

G. Vitale, M. Caraglia, A. Ciccarelli, G. Lupoli, A. Abbruzzese, P. Tagliaferri, et al.

Current approaches and perspectives in the therapy of medullary thyroid carcinoma.

Cancer, 91 (2001), pp. 1797-1808

[12.]

F. Orlandi, P. Caraci, A. Mussa, E. Saggiorato, G. Pancani, A. Angeli.

Treatment of medullary thyroid carcinoma: an update.

Endocr Relat Cancer, 8 (2001), pp. 135-147

Medline

[13.]

L.E. Tisell, W.G. Dilley, S.A. Wells Jr.

Progression of postoperative medullary thyroid carcinoma as monitored by plasma calcitonin levels.

Surgery, 119 (1996), pp. 34-39

Medline

[14.]

J.A. Van Heerden, C.S. Grant, H. Gharib, I. Hay, D.M. Ilstrup.

Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Ann Surg, 204 (1990), pp. 395-401

[15.]

R.M. Hofstra, R.M. Landsvater, I. Ceccherini, R.P. Stulp, T. Stelwagen, Y. Luo, et al.

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.

J Clin Endocrinol Metab, 82 (1997), pp. 4176-4178

http://dx.doi.org/10.1210/jcem.82.12.4439 | Medline

[16.]

M. Rossel, I. Schuffenecker, M. Schlumberger, C. Bonnardel, E. Modigliani, P. Gardet, et al.

A single point mutation in the RET proto-oncogene is associated with the majority of NEM 2B.

Hum Genet, 35 (1995), pp. 403-406

[17.]

K.M. Carlson, J. Bracamontes, C.E. Jackson, R. Clark, A. Lacroix, S.A. Wells Jr, et al.

Parent-of-origin effects in multiple endocrine neoplasia type 2B.

Am J Hum Genet, 55 (1994), pp. 1076-1082

Medline

[18.]

S. Leboulleux, J.P. Travagli, B. Caillou, A. Laplanche, J.M. Bidar, M. Schlumberger, et al.

Medullary thyroid carcinoma as a part of a multiple endocrine neoplasia type 2B syndrome, influence of the stage on the clinical course.

Cancer, 94 (2002), pp. 44-50

Medline

[19.]

M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, et al.

Guidelines for diagnosis and therapy of NEM type 1 and type 2.

J Clin Endocrinol Metab, 86 (2001), pp. 5658-5671

http://dx.doi.org/10.1210/jcem.86.12.8070 | Medline

Publicación continuada como Endocrinología, Diabetes y Nutrición. Más información

Indexada en:

Síguenos:

Publicación continuada como Endocrinología, Diabetes y Nutrición. Más información

Indexada en:

Síguenos:

Suscríbase a la newsletter